Transcriptional control of leukemogenesis by the chromatin reader SGF29
- 22 February 2024
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 143 (8) , 697-712
Abstract
Aberrant expression of stem cell–associated genes is a common feature in acute myeloid leukemia (AML) and is linked to leukemic self-renewal and therapy resistance. Using AF10-rearranged leukemia as a prototypical example of the recurrently activated “stemness” network in AML, we screened for chromatin regulators that sustain its expression. We deployed a CRISPR-Cas9 screen with a bespoke domain-focused library and identified several novel chromatin-modifying complexes as regulators of the TALE domain transcription factor MEIS1, a key leukemia stem cell (LSC)–associated gene. CRISPR droplet sequencing revealed that many of these MEIS1 regulators coordinately controlled the transcription of several AML oncogenes. In particular, we identified a novel role for the Tudor-domain–containing chromatin reader protein SGF29 in the transcription of AML oncogenes. Furthermore, SGF29 deletion impaired leukemogenesis in models representative of multiple AML subtypes in multiple AML subtype models. Our studies reveal a novel role for SGF29 as a nononcogenic dependency in AML and identify the SGF29 Tudor domain as an attractive target for drug discovery.Keywords
This publication has 57 references indexed in Scilit:
- KAT2A affects tumor metabolic reprogramming in colon cancer progression through epigenetic activation of E2F1Human Cell, 2022
- The Ada2/Ada3/Gcn5/Sgf29 histone acetyltransferase moduleBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2021
- Targeting epigenetic reader domains by chemical biologyCurrent Opinion in Chemical Biology, 2020
- Acute myeloid leukemia driven by the CALM-AF10 fusion gene is dependent on BMI1Experimental Hematology, 2019
- A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid LeukemiaCell Reports, 2016
- AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML SubtypesCancer Cell, 2014
- Selective Killing of Mixed Lineage Leukemia Cells by a Potent Small-Molecule DOT1L InhibitorCancer Cell, 2011
- MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1LCancer Cell, 2011
- Quantitative Interaction Proteomics and Genome-wide Profiling of Epigenetic Histone Marks and Their ReadersCell, 2010
- hDOT1L Links Histone Methylation to LeukemogenesisCell, 2005